Biotech Values

[Praveen]

Though the Lucentis & Regeneron VEGF TRAP P1 trials are different in AMD, I like REGN's efficacy data and the fact that REGN might include Lucentis as control arm in P3.

A quick visit to the P1 trial of Lucentis:

http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=6487

http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=5527

Praveen

PS:Single doses of the VEGF Trap were generally well tolerated at all dose levels tested (0.05 to 4 mg), with no systemic or serious adverse events reported. Dose escalation to the highest planned dose was achieved without reaching a maximum tolerated dose (MTD).